Rational design and development of new anthracenedione derivatives

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/487333

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Our laboratory has discovered a way to activate the anti-cancer drug mitoxantrone to make it bind to DNA more effectively. This involves pre-activating it with the simple molecule formaldehyde. This concept has enabled us to design new anticancer drugs that are predicted to be more effective at killing cancer cells. In this study we will synthesise these new compounds then test how effectively they bind to DNA, inhibit growth of tumour cells in culture, and inhibit growth of tumours in mice.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $471,702.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Endodontics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA adducts | DNA-targeted drugs | cancer chemotherapeutic agents | cancer chemotherapy | drug design | mitoxantrone | pixantrone | rational drug design | treatment of cancer

Related Links